Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial

A. Perez, Edith; J. Suman, Vera; E. Davidson, Nancy; W. Sledge, George; A. Kaufman, Peter; A. Hudis, Clifford; Martino, Silvana; R. Gralow, Julie; R. Dakhil, Shaker; N. Ingle, James; P. Winer, Eric; A. Gelmon, Karen; J. Gersh, Bernard; S. Jaffe, Allan; J. Rodeheffer, Richard

doi:10.1200/jco.2007.13.5467

Public

Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial

Published in Journal of Clinical Oncology • Feb 5, 2008

Authors:

Edith A. Perez

Vera J. Suman

Nancy E. Davidson

Abstract

PURPOSE: To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial. PATIENTS AND METHODS: Patients with HER2-positive operable breast cancer were randomly assigned to doxorubicin plus cyclophosphamide (AC) follo...

Subject

Trastuzumab

Medicine

Ejection fraction

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!